These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1055 related items for PubMed ID: 31018157

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
    Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E.
    Headache; 2018 Nov; 58(10):1689-1696. PubMed ID: 30426478
    [Abstract] [Full Text] [Related]

  • 6. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ.
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [Abstract] [Full Text] [Related]

  • 7. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
    Cohen F, Yuan H, Silberstein SD.
    BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L, Haanes KA, Warfvinge K, Krause DN.
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J, Manise M, Nonis R, Gérard P, Timmermans G.
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [Abstract] [Full Text] [Related]

  • 16. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R, Olesen J.
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [Abstract] [Full Text] [Related]

  • 17. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
    Nagaraj K, Vandenbussche N, Goadsby PJ.
    Neurol India; 2021 Jun; 69(Supplement):S59-S66. PubMed ID: 34003149
    [Abstract] [Full Text] [Related]

  • 18. Monoclonal antibodies for the prevention of migraine.
    Raffaelli B, Neeb L, Reuter U.
    Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
    [Abstract] [Full Text] [Related]

  • 19. The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms.
    González-Hernández A, Marichal-Cancino BA, García-Boll E, Villalón CM.
    CNS Neurol Disord Drug Targets; 2020 Dec; 19(5):344-359. PubMed ID: 32552657
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.